{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:22:15Z","timestamp":1794939735763,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Repare Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Predictive biomarkers of response are essential to effectively guide targeted cancer treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown to be synthetic lethal with loss of function (LOF) of ataxia telangiectasia-mutated (ATM) kinase, and preclinical studies have identified ATRi-sensitizing alterations in other DNA damage response (DDR) genes. Here we report the results from module 1 of an ongoing phase 1 trial of the ATRi camonsertib (RP-3500) in 120 patients with advanced solid tumors harboring LOF alterations in DDR genes, predicted by chemogenomic CRISPR screens to sensitize tumors to ATRi. Primary objectives were to determine safety and propose a recommended phase 2 dose (RP2D). Secondary objectives were to assess preliminary anti-tumor activity, to characterize camonsertib pharmacokinetics and relationship with pharmacodynamic biomarkers and to evaluate methods for detecting ATRi-sensitizing biomarkers. Camonsertib was well tolerated; anemia was the most common drug-related toxicity (32% grade 3). Preliminary RP2D was 160\u2009mg weekly on days 1\u20133. Overall clinical response, clinical benefit and molecular response rates across tumor and molecular subtypes in patients who received biologically effective doses of camonsertib (&gt;100\u2009mg\u2009d\n                    <jats:sup>\u22121<\/jats:sup>\n                    ) were 13% (13\/99), 43% (43\/99) and 43% (27\/63), respectively. Clinical benefit was highest in ovarian cancer, in tumors with biallelic LOF alterations and in patients with molecular responses. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04497116\">NCT04497116<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02399-0","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T12:02:25Z","timestamp":1685966545000},"page":"1400-1411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-7853","authenticated-orcid":false,"given":"Elizabeth K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1850-535X","authenticated-orcid":false,"given":"Martin","family":"H\u00f8jgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika B.","family":"Mettu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito A.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-5040","authenticated-orcid":false,"given":"Joseph D.","family":"Schonhoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Wainszelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-1662","authenticated-orcid":false,"given":"Adrian J.","family":"Fretland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Ulanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Rimkunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Zinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-6726","authenticated-orcid":false,"given":"Ian M.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2969-3173","authenticated-orcid":false,"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"2399_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"2399_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0955-0674(00)00201-5","volume":"13","author":"D Durocher","year":"2001","unstructured":"Durocher, D. & Jackson, S. P. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opin. Cell Biol. 13, 225\u2013231 (2001).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2399_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard, H., Garcia-Muse, T. & Aguilera, A. Replication stress and cancer. Nat. Rev. Cancer 15, 276\u2013289 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2399_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, M. J. Targeting the DNA damage response in cancer. Mol. Cell 60, 547\u2013560 (2015).","journal-title":"Mol. Cell"},{"key":"2399_CR5","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","volume":"11","author":"J Setton","year":"2021","unstructured":"Setton, J. et al. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 11, 1626\u20131635 (2021).","journal-title":"Cancer Discov."},{"key":"2399_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pilie","year":"2019","unstructured":"Pilie, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 81\u2013104 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2399_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391 (2021).","journal-title":"Cancer Discov."},{"key":"2399_CR8","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","volume":"123","author":"CR Dunlop","year":"2020","unstructured":"Dunlop, C. R. et al. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Br. J. Cancer 123, 1424\u20131436 (2020).","journal-title":"Br. J. Cancer"},{"key":"2399_CR9","doi-asserted-by":"publisher","first-page":"190156","DOI":"10.1098\/rsob.190156","volume":"9","author":"N Hustedt","year":"2019","unstructured":"Hustedt, N. et al. A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol. 9, 190156 (2019).","journal-title":"Open Biol."},{"key":"2399_CR10","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","volume":"38","author":"C Wang","year":"2019","unstructured":"Wang, C. et al. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene 38, 2451\u20132463 (2019).","journal-title":"Oncogene"},{"key":"2399_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","volume":"182","author":"M Olivieri","year":"2020","unstructured":"Olivieri, M. et al. A genetic map of the response to DNA damage in human cells. Cell 182, 481\u2013496 (2020).","journal-title":"Cell"},{"key":"2399_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson, C. T. et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat. Commun. 7, 13837 (2016).","journal-title":"Nat. Commun."},{"key":"2399_CR13","doi-asserted-by":"publisher","first-page":"111081","DOI":"10.1016\/j.celrep.2022.111081","volume":"40","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann, M. et al. Guiding ATR and PARP inhibitor combinationswith chemogenomic screens. Cell Rep. 40, 111081 (2022).","journal-title":"Cell Rep."},{"key":"2399_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","volume":"21","author":"A Roulston","year":"2022","unstructured":"Roulston, A. et al. RP-3500: a novel, potent, and selective ATR Inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors. Mol. Cancer Ther. 21, 245\u2013256 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2399_CR15","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","volume":"74","author":"KN Mohni","year":"2014","unstructured":"Mohni, K. N., Kavanaugh, G. M. & Cortez, D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res. 74, 2835\u20132845 (2014).","journal-title":"Cancer Res."},{"key":"2399_CR16","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.celrep.2020.01.020","volume":"30","author":"KD Fagan-Solis","year":"2020","unstructured":"Fagan-Solis, K. D. et al. A P53-independent DNA damage response suppresses oncogenic proliferation and genome instability. Cell Rep. 30, 1385\u20131399 e1387 (2020).","journal-title":"Cell Rep."},{"key":"2399_CR17","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1093\/nar\/gkp262","volume":"37","author":"M Katsura","year":"2009","unstructured":"Katsura, M. et al. The ATR-Chk1 pathway plays a role in the generation of centrosome aberrations induced by Rad51C dysfunction. Nucleic Acids Res. 37, 3959\u20133968 (2009).","journal-title":"Nucleic Acids Res."},{"key":"2399_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.celrep.2019.09.008","volume":"29","author":"S Saxena","year":"2019","unstructured":"Saxena, S., Dixit, S., Somyajit, K. & Nagaraju, G. ATR signaling uncouples the role of RAD51 paralogs in homologous recombination and replication stress response. Cell Rep. 29, 551\u2013559 (2019).","journal-title":"Cell Rep."},{"key":"2399_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1689-8","volume":"10","author":"LR Gomes","year":"2019","unstructured":"Gomes, L. R. et al. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. Cell Death Dis. 10, 459 (2019).","journal-title":"Cell Death Dis."},{"key":"2399_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jmoldx.2023.02.004","volume":"25","author":"D Glodzik","year":"2023","unstructured":"Glodzik, D. et al. Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin-embedded tumor samples using a novel tumor-only sequencing panel. J. Mol. Diagn. 25, 295\u2013310 (2023).","journal-title":"J. Mol. Diagn."},{"key":"2399_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111\u20131115 (2008).","journal-title":"Nature"},{"key":"2399_CR22","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt, B. et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin. Cancer Res. 23, 6708\u20136720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2399_CR23","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap, T. A. et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 38, 3195\u20133204 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2399_CR24","doi-asserted-by":"publisher","first-page":"v165","DOI":"10.1093\/annonc\/mdz244.012","volume":"30","author":"M Dillon","year":"2019","unstructured":"Dillon, M. et al. A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B). Ann. Oncol. 30, v165\u2013v166 (2019).","journal-title":"Ann. Oncol."},{"key":"2399_CR25","doi-asserted-by":"publisher","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2022-CT006","volume":"82","author":"TA Yap","year":"2022","unstructured":"Yap, T. A. et al. Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects. Cancer Res. 82, CT006 (2022).","journal-title":"Cancer Res."},{"key":"2399_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network.","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"2399_CR27","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","volume":"75","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi, R. et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 75, 628\u2013634 (2015).","journal-title":"Cancer Res."},{"key":"2399_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25904-w","volume":"12","author":"PA Konstantinopoulos","year":"2021","unstructured":"Konstantinopoulos, P. A. et al. A replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat. Commun. 12, 5574 (2021).","journal-title":"Nat. Commun."},{"key":"2399_CR29","first-page":"1","volume":"40","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A., Lheureux, S. & Moore, K. N. PARP inhibitors for ovarian cancer: current indications, future combinations, and novel assets in development to target DNA damage repair. Am. Soc. Clin. Oncol. Educ. Book 40, 1\u201316 (2020).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2399_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","volume":"22","author":"A da Costa","year":"2023","unstructured":"da Costa, A. et al. Targeting replication stress in cancer therapy. Nat. Rev. Drug Discov. 22, 38\u201358 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2399_CR31","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/nm.3729","volume":"20","author":"Z Zheng","year":"2014","unstructured":"Zheng, Z. et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20, 1479\u20131484 (2014).","journal-title":"Nat. Med."},{"key":"2399_CR32","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2399_CR33","unstructured":"Breast Cancer Association Consortium et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 8, e216744 (2022)."},{"key":"2399_CR34","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/jnci\/djy028","volume":"110","author":"B Weigelt","year":"2018","unstructured":"Weigelt, B. et al. The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers. J. Natl Cancer Inst. 110, 1030\u20131034 (2018).","journal-title":"J. Natl Cancer Inst."},{"key":"2399_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0951-9","volume":"20","author":"AL Renault","year":"2018","unstructured":"Renault, A. L. et al. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Res. 20, 28 (2018).","journal-title":"Breast Cancer Res."},{"key":"2399_CR36","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1200\/JCO.2005.01.3698","volume":"23","author":"E Honrado","year":"2005","unstructured":"Honrado, E. et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J. Clin. Oncol. 23, 7503\u20137511 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2399_CR37","doi-asserted-by":"crossref","unstructured":"Breast Cancer Association Consortium et al. Breast cancer risk genes\u2014association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428\u2013439 (2021).","DOI":"10.1056\/NEJMoa1913948"},{"key":"2399_CR38","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0092-8674(00)81302-1","volume":"85","author":"R Hakem","year":"1996","unstructured":"Hakem, R. et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009\u20131023 (1996).","journal-title":"Cell"},{"key":"2399_CR39","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.1073\/pnas.0503793102","volume":"102","author":"S Furuta","year":"2005","unstructured":"Furuta, S. et al. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc. Natl Acad. Sci. USA 102, 9176\u20139181 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2399_CR40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 155, 1088\u20131103 (2013).","journal-title":"Cell"},{"key":"2399_CR41","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1038\/onc.2015.24","volume":"34","author":"N Kanu","year":"2015","unstructured":"Kanu, N. et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 34, 5699\u20135708 (2015).","journal-title":"Oncogene"},{"key":"2399_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister, S. X. et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell 28, 557\u2013568 (2015).","journal-title":"Cancer Cell"},{"key":"2399_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","volume":"18","author":"LI Toledo","year":"2011","unstructured":"Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721\u2013727 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2399_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI58928","volume":"122","author":"DW Schoppy","year":"2012","unstructured":"Schoppy, D. W. et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 122, 241\u2013252 (2012).","journal-title":"J. Clin. Invest."},{"key":"2399_CR45","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41388-021-02162-0","volume":"41","author":"S Guerrero Llobet","year":"2022","unstructured":"Guerrero Llobet, S. et al. An mRNA expression-based signature for oncogene-induced replication-stress. Oncogene 41, 1216\u20131224 (2022).","journal-title":"Oncogene"},{"key":"2399_CR46","doi-asserted-by":"publisher","first-page":"e2100531","DOI":"10.1200\/PO.21.00531","volume":"6","author":"ES Sokol","year":"2022","unstructured":"Sokol, E. S. et al. PARP inhibitor insensitivity to BRCA1\/2 monoallelic mutations in microsatellite instability-high cancers. JCO Precis. Oncol. 6, e2100531 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"2399_CR47","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2399_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","volume":"28","author":"ES Kim","year":"2022","unstructured":"Kim, E. S. et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat. Med. 28, 939\u2013945 (2022).","journal-title":"Nat. Med."},{"key":"2399_CR49","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","volume":"82","author":"JC Stadler","year":"2022","unstructured":"Stadler, J. C. et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 82, 349\u2013358 (2022).","journal-title":"Cancer Res."},{"key":"2399_CR50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/1541-7786.MCR-19-0768","volume":"18","author":"KCS Oliveira","year":"2020","unstructured":"Oliveira, K. C. S. et al. Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of cancer. Mol. Cancer Res. 18, 517\u2013528 (2020).","journal-title":"Mol. Cancer Res."},{"key":"2399_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer 1, 276\u2013290 (2020).","journal-title":"Nat. Cancer"},{"key":"2399_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223\u2013238 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2399_CR53","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.3369","volume":"19","author":"CJ Lord","year":"2013","unstructured":"Lord, C. J. & Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 19, 1381\u20131388 (2013).","journal-title":"Nat. Med."},{"key":"2399_CR54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/2159-8290.CD-17-0734","volume":"7","author":"SM Domchek","year":"2017","unstructured":"Domchek, S. M. Reversion mutations with clinical use of PARP inhibitors: many genes, many versions. Cancer Discov. 7, 937\u2013939 (2017).","journal-title":"Cancer Discov."},{"key":"2399_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2021.11.011","volume":"163","author":"R Plummer","year":"2022","unstructured":"Plummer, R. et al. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer 163, 19\u201326 (2022).","journal-title":"Lung Cancer"},{"key":"2399_CR56","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374\u2013382 (2017).","journal-title":"Cell Stem Cell"},{"key":"2399_CR57","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1158\/1078-0432.CCR-17-2494","volume":"24","author":"KC Kurnit","year":"2018","unstructured":"Kurnit, K. C. et al. Precision oncology decision support: current approaches and strategies for the future. Clin. Cancer Res. 24, 2719\u20132731 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2399_CR58","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","volume":"22","author":"Y Yuan","year":"2016","unstructured":"Yuan, Y., Hess, K. R., Hilsenbeck, S. G. & Gilbert, M. R. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin. Cancer Res. 22, 4291\u20134301 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2399_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R. et al. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"2399_CR60","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"2399_CR61","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson, R., Boisvert, J. L., Benes, C. H. & Zou, L. Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase. Mol. Cell 59, 1011\u20131024 (2015).","journal-title":"Mol. Cell"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02399-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T07:42:58Z","timestamp":1687419778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02399-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2399"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02399-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.Y. is an employee of The University of Texas MD Anderson Cancer Center and medical director of the Institute for Applied Cancer Science, which has a commercial interest in DDR and other inhibitors; has received funding paid to their institution from Acrivon, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, Bristol Myers Squibb, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, Vivace and Zenith; has received consultancy funding from AbbVie, AstraZeneca, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Bayer, BeiGene, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Clovis, Cybrexa, Diffusion, EMD Serono, F-Star, Genmab, Glenmark, GLG, Globe Life Sciences, GlaxoSmithKline, Guidepoint, Idience, Ignyta, I-Mab, ImmuneSensor, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI Pharma, Mereo, Merck, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER, Pfizer, Piper-Sandler, Prolynx, Repare, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs and ZielBio; and is a stockholder in Seagen. E.F. has received personal funding for conference attendance from Repare Therapeutics, CARIS Life Science, Seagen and Sapience Pharma and has received research funding paid to their institution by Repare Therapeutics, Bicycle Therapeutics, Artios Pharma, Seagen, Amgen, Nurix Therapeutics, BioNTech, Relay Therapeutics, Tahio Pharmaceutical, Pfizer, Roche, Daiichi Sankyo, Gilead Sciences, Basilea Pharmaceutica, Jiangsu Hengrui Medicine, Mereo Biopharma, HUTCHMED, Merus, Crescendo Biologics, GlaxoSmithKline, BeiGene, Turning Point Therapeutics and Sapience Pharma. E.K.L. has received research funding from Merck and consulting funding from Aadi Biosciences. D.R.S. has received research funding paid to their institution by Aeglea Biotherapeutics, Agios, Amgen, AnHeart Therapeutics, Apollomics, Arcus, Arrys Therapeutics, Ascendis Pharma, Astellas, AstraZeneca, Bayer, BeiGene, BIND Therapeutics, BioNTech, Blueprint Medicine, Boehringer lngelheim, Bristol Myers Squibb, Calithera, Celgene, Celldex, Clovis, Cyteir Therapeutics, Daiichi Sankyo, Denovo Biopharma, Eisai, Elevation Oncology, Endeavor, Erasca, Faeth Therapeutics, Fujifilm Pharmaceuticals, G1 Therapeutics, Roche\/Genentech, Gilead Sciences, GlaxoSmithKline, GRAIL, Hutchison MediPharma, ImClone Systems, Incyte, Ipsen, Janssen, Jazz Pharmaceuticals, Kronos Bio, Eli Lilly, Loxo Oncology, Lyell Immunopharma, MacroGenics, MedImmune, Merck, Molecular Template, Nektar, Neon Therapeutics, Novartis, Novocure, Pure Tech Health, Razor Genomics, Repare Therapeutics, Rgenix, Seagen, Shenzhen Chipscreen Biosciences, Sythekine, Taiho, Tango Therapeutics, Tarveda, Tesaro, Tizona Therapeutics, Transgene, The University of Texas Southwestern, Verastem and Zai Laboratory and has performed a consultant and\/or advisory role paid to their institution by AstraZeneca, BeiGene, Bristol Myers Squibb, Curio Science, EMO Serano, Evidera, GlaxoSmithKline, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Eli Lilly, Molecular Templates, Monte Rosa Therapeutics, Novartis, Novocure, Pfizer, Pyxis Oncology, Regeneron Pharmaceuticals, Roche\/Genentech and Sanofi. M.H. has received research funding paid to their institution by Repare Therapeutics and Roche. S.L. has received grants or contracts paid to their institution from Merck, AstraZeneca, Regeneron, Roche, Repare Therapeutics, GlaxoSmithKline and Seagen; consulting fees from Novocure, Merck, AstraZeneca, GlaxoSmithKline, Eisai and Shattuck Labs; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline and Eisai\/Merck; and participation on a data safety monitoring board or advisory board from AstraZeneca. N.B.M. has received research funding paid to their institution by Incyte Corporation, Genentech\/Roche, AstraZeneca, Amgen, Erytech Pharma, Bristol Myers Squibb, Amphivena Therapeutics, Repare Therapeutics, BioMed Valley Discoveries, Mereo Biopharma, Syros, Aravive and Merck. B.A.C. has received research funding paid to their institution by AstraZeneca, Abbvie, Actuate Therapeutics, Astellas, Bayer, Dragonfly Therapeutics, Pfizer and Repare Therepeutics. L.C. has received research funding paid to their institution by Repare Therapeutics. R.P. has received honoria for attending advisory boards from Pierre Faber, Bayer, Novartis, Bristol Myers Squibb, Cybrexa, Ellipses, CV6 Therapeutics, Immunocore, Genmab, Astex Therapeutics, Medivir, Onxeo and Sanofi; honoraria for working as an independent data monitoring committee member for Alligator Biosciences, GlaxoSmithKline and SOTIO Biotech AG; personal funding for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer and Bristol Myers Squibb; and funds to support attendance at conferences from Merck Sharp & Dohme and Bristol Myers Squibb. G.M.C. has received funding paid to their institution by Servier Pharmaceuticals, Epizyme, PharmaMar, Macrogenics, Eisai, Merck KGaA\/EMO Sereno Research and Development Institute, Bavarian-Nordic, Bayer, SpringWorks, Repare Therapeutics, Foghorn, SMP Oncology, Jazz Pharmaceuticals, RAIN Therapeutics, BioAtla, lnhibrx, lkena and C4 Therapeutics; and advisory board fees from Epizyme, PharmaMar, Eisai, Foghorn, lkena and C4 Therapeutics. F.M.B. has received research funding to their institution from Aileron Therapeutics, AstraZeneca, Bayer, Calithera, Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm, eFFECTOR Therapeutics, Genentech, Guardant Health, Klus Pharma, Takeda, Novartis, Puma Biotechnology and Taiho; funding for consultancy from AbbVie, Aduro BioTech, Alkermes, AstraZeneca, Daiichi Sankyo, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche, GT Apeiron, Genentech, Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer, Protai Bio, Samsung Bioepis, Seattle Genetics, Tallac Therapeutics, Tyra Biosciences, Xencor and Zymeworks; fees from advisory committees from Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology, Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals and Zentalis; and honoraria from Chugai Biopharmaceuticals. J.O. has received consultancy fees from Repare Therapeutics. J.D.S., M.W., A.F., D.U., M.Z., M.K., I.M.S. and V.R. are current employees and shareholders of Repare Therapeutics. Y.X. is a current employee of Repare Therapeutics. P.M. is a former employee and current shareholder of Repare Therapeutics. M.K., I.M.S., V.R. and J.S.R.F. have a provisional patent related to data disclosed in this publication. J.S.R.F. has received consultancy fees from Goldman Sachs, Paige.AI, Repare Therapeutics and Personalis; is a member of the scientific advisory boards of Volition Rx, Paige.AI, Repare Therapeutics, Personalis and Bain Capital; is a member of the board of directors of Grupo Oncoclinicas; and is an ad hoc member of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, AstraZeneca, Daiichi Sankyo and Merck Sharp & Dohme. E.R. has no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}